Akebia Therapeutics Profit Margin

The latest profit margin for AKBA is -8.83% as of March 2026. That compares with -24.75% in the prior-year period — up 64.3% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Akebia Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AKBA's profit margin moved from -24.75% to -8.83% — a 64.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Akebia Therapeutics's valuation or profitability profile.

Against Healthcare companies, AKBA currently prints -8.83% for profit margin, while the sector average sits near 15.58%. That is roughly 156.6% below the sector mean. Large gaps often invite a closer look at Akebia Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Akebia Therapeutics converts resources into returns. At -8.83%, AKBA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -24.75% in the prior-year period — up 64.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AKBA's profit margin (-8.83%), review year-over-year change from -24.75%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.